Ambroxol HCl

Quick links to important sections

Ambroxol HCl

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ambroxol HCl

Quick Facts

Property Description
Active ingredient Ambroxol hydrochloride
Form Tablet, syrup, oral solution, injectable solution
Pharmacological class Mucolytic agent, secretolytic agent
General purpose Clearing thick respiratory secretions
Origin Synthetic derivative of bromhexine

Defining Ambroxol hydrochloride: An Identity and Class Overview

Ambroxol hydrochloride is a synthetic pharmaceutical agent that is clinically recognized as a mucolytic agent and a secretolytic agent. This precise classification distinguishes it from simple cough suppressants, defining its function by its interaction with and modification of mucus. The hydrochloride salt form of Ambroxol is the globally standardized International Nonproprietary Name (INN) compound, ensuring its consistent manufacturing and reliable pharmaceutical properties.

Structurally, Ambroxol is a synthetic active metabolite derived from the bromhexine molecule. This specific relationship confers unique properties, supporting a potent and direct effect on the respiratory lining compared to its parent substance.

Composition, Form, and General Purpose

The compound is typically employed as a single-ingredient product, available for both oral delivery, using tablets or flavored syrups, and for specialized parenteral use or topical inhalation. The versatility of its formulation allows the medicine to be adapted for different patient groups, including those who may require administration via oral solution.

The general therapeutic purpose of this secretolytic agent is to support the body in clearing the airways when they are congested by thick, sticky mucus. Ambroxol’s primary mucolytic function is to reduce the viscosity of respiratory secretions and enhance mucociliary clearance. This pharmacological action is generally utilized in scenarios involving thick mucus, such as during persistent upper respiratory issues, to facilitate the removal of secretions.

Regulatory References

  1. U.S. National Library of Medicine

What side effects are possible with Ambroxol HCl?

Possible Side Effects and Safety Information

Adverse reactions associated with Ambroxol hydrochloride are classified in official regulatory documents based on frequency and the affected body system. The vast majority of documented effects are categorized within the Gastrointestinal Disorders and the Immune System Disorders.

Frequency Classification of Adverse Reactions

Classification Examples of Reactions Affected Systems (SOC)
Common Nausea, Diarrhoea, Dysgeusia (changed taste), Oral/Pharyngeal Hypoesthesia Gastrointestinal, Nervous
Uncommon Vomiting, Abdominal pain, Dyspepsia, Dry mouth, Fever Gastrointestinal, General
Rare Hypersensitivity reactions, Rash, Urticaria, Dry throat Immune System, Skin
Not Known Anaphylactic shock, Severe cutaneous adverse reactions (SCARs), Angioedema Immune System, Skin

Serious Adverse Reactions and Safety Constraints

The regulatory safety profile explicitly documents the potential for Serious Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). These are classified as having an unknown frequency but are significant safety concerns; the appearance of a progressive skin rash is a documented signal that requires the cessation of treatment.

Regarding population-specific safety, official labeling advises caution in individuals with severe renal impairment due to the expected accumulation of metabolites, and in those with severe hepatic impairment. Caution is also noted for patients with compromised airways motility due to the risk of mucus obstruction, and for those with a history of peptic ulcer disease. The medicine is not generally recommended for use during the first trimester of pregnancy.

Overdose and Emergency Response

Ambroxol HCl Overdose and when to seek help

The official regulatory documents provide clear guidance on over-exposure to Ambroxol hydrochloride. It is officially documented that no specific overdose symptoms have been reported in humans to date. Instead, the manifestations observed in cases of accidental overdosage are consistent with the medicine's known side effects, which may include short-term restlessness, diarrhoea, nausea, or vomiting. Serious symptoms were not recorded, though extreme overdosage may potentially involve symptoms like hypotension.


Immediate Emergency Actions and Supportive Care

A core regulatory finding is that there is no specific antidote for Ambroxol overdose. Consequently, the required management approach is primarily symptomatic treatment. Acute procedural measures, such as gastric lavage or the administration of an antiemetic, are not generally indicated but may be considered only in cases of very high overdosage.


When Urgent Medical Help Is Required

Immediate medical attention is officially required if an individual experiences signs of severe reactions, which may manifest during an overdose scenario. Treatment must be discontinued immediately if there is any evidence of a progressive skin rash, mucosal lesions, or other signs consistent with anaphylaxis or severe cutaneous adverse reactions. Seeking immediate medical attention is mandatory under these conditions, as these are officially recognized as severe, life-threatening outcomes.

Therapeutic Uses of Ambroxol HCl

Ambroxol HCl is considered relevant across therapeutic domains where additional symptomatic support is needed for respiratory conditions, and is relevant in contexts marked by increased discomfort or tension caused by thick, excessive mucus. As a mucoactive agent, it may assist with symptoms that interfere with daily functioning.

The medication is commonly used to help with symptoms linked to organ-specific functional stress of airway diseases associated with abnormal mucous secretion and transport. This is applied in addressing various conditions involving episodic or fluctuating manifestations, such as bronchitis, asthmatic bronchitis, and bronchial asthma, where it serves as a mucolytic therapy for the treatment of airway diseases.

The drug contributes to easing the overall symptom load and supports general well-being during periods of heightened symptoms. It may assist with maintaining functional stability and helps patients cope more steadily with symptom fluctuations.


Quick Fact: Applied in addressing Productive Cough

Regulatory References

  1. Health Products Regulatory Authority (HPRA) Summary of Product Characteristics

Eligibility and Restrictions for Use

The official regulatory documents define clear population eligibility rules for Ambroxol hydrochloride. The medicine is contraindicated for individuals with a known hypersensitivity to the active substance, its metabolite bromhexine, or any of the product’s excipients. Certain oral formulations are also contraindicated in patients with specific hereditary metabolic conditions, such as hereditary fructose or galactose intolerance, depending on the excipients used.

For general secretolytic use, the medicine is typically not recommended in children under 2 years of age in many regions. Use is generally established for adults, adolescents, and children above this age threshold.

The medicine requires special caution and restriction in several adult patient groups. This includes individuals with severe renal impairment or severe hepatic impairment, where a dose reduction or extended dosing interval may be mandated due to the risk of metabolite accumulation. Caution is also officially advised for patients with a history of peptic or gastric ulceration and those with compromised airway motility.

For women who are pregnant, use is not recommended during the first trimester. During the later trimesters, administration should only proceed if the benefit is determined to outweigh the potential risk. As Ambroxol is excreted into breast milk, its use is not recommended while breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents describe specific interactions for Ambroxol HCl with two main categories of medicines, based on effects that are either pharmacokinetic (related to drug concentration) or pharmacodynamic (related to the effect on the body).

Documented Interactions and Restrictions

The primary interaction constraints involve the potential effects on the local concentration of certain co-administered drugs and an increased risk associated with impaired clearance of secretions.

Medicine Category Specific Interacting Medicines Interaction Implication and Constraint
Antibiotics Amoxicillin, Cefuroxime, Erythromycin, Doxycycline Concomitant administration has been documented to result in increased concentrations of these antibiotics in bronchial secretions and sputum.
Antitussives (Cough Suppressants) Not typically listed by specific name; refers to the class. Combination is generally not recommended because the suppression of the cough reflex can lead to a dangerous build-up of secretions in the bronchi. This represents a restriction based on safety concerns related to the drug’s intended effect.

These interaction statements define the product's official interaction profile, focusing on pharmacokinetic changes that enhance specific antibiotic distribution and a pharmacodynamic constraint that requires avoiding co-administration with cough suppressants to prevent the accumulation of mucus. These requirements structure how the medicine is to be managed when used with other therapies.

Mechanism of Action

Modulation of Mucus Properties and Secretion

Ambroxol acts as a mucoactive agent that engages Type II Pneumocytes to stimulate the release of pulmonary surfactant. This mechanism modifies the physical properties of bronchial secretions, lowering the viscosity and adhesion of mucus, which supports mucociliary transport.

Peripheral Na^+ Channel Blockade

The drug modulates sensory nerve signaling by acting as an antagonist of voltage-gated sodium ( Na^+) channels on peripheral sensory neurons. The inhibition of nerve depolarization generates a local anesthetic effect on the sensory neurons of the mucous membranes.

Influencing Inflammatory Mediators and Oxidative Processes

Ambroxol influences the inflammatory pathway by scavenging reactive oxygen species (ROS) and inhibiting the release of pro-inflammatory cytokines (e.g., IL-1beta) from immune cells. This action contributes to the reduction of local inflammatory markers within the respiratory tract.

Dosage and Administration Information

How to use Ambroxol HCl

Ambroxol hydrochloride is administered via multiple routes, including the primary oral route (tablets, syrups, drops) and specialized parenteral (injection) or inhalation (nebulizer solution) routes. The standard adult oral regimen involves an initial phase of 30 mg three times daily, often for the first 2–3 days, before transitioning to a maintenance dose of 30 mg twice daily. The sustained-release capsule form, typically 75 mg, is taken once daily. Dosing recommendations are based on specific formulations and strengths.

The immediate-release formulations are administered in divided daily doses and are generally taken after a meal along with adequate fluid to support administration. Proper use involves specific handling for certain forms; for example, sustained-release capsules must be swallowed whole and must not be crushed or chewed. When using liquid forms, the correct dose is measured using the attached dosing device.

Specific procedural adjustments are noted for certain populations. For patients with severe renal or hepatic impairment, the dosing interval is extended, or the dose reduced (e.g., by 50%) to account for altered elimination. Use is typically limited to 4 to 5 days without a medical review.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Summary

Studies have investigated whether the drug (Compound X) was examined in research evaluating treatments for moderate-to-severe chronic conditions. Research explored the outcomes observed in participants receiving this combination over a 12-week period.

One study investigated the potential for an association with a change in quality-of-life scores when compared to a placebo group. Findings from the key trial detailed the differences between the Compound X group and the placebo group.


Key Study Findings

Trial 1: Chronic Condition Management

This randomized, double-blind, placebo-controlled trial focused on whether Compound X was the subject of research exploring approaches for managing the chronic condition. The primary outcome was the change in a validated symptom-severity score (the Pain & Impairment Scale, PIS) after 8 weeks of treatment.

  • The PIS score in the Compound X group decreased by a mean of 4.2 points (baseline 18.5, endpoint 14.3, p=0.04).
  • The PIS score in the placebo group decreased by a mean of 1.1 points (baseline 18.9, endpoint 17.8, p=0.51).

Trial 2: Quality of Life Analysis

Research has reported findings suggesting that the addition of a secondary agent examined the severity of flare-ups in a population including participants with a history of difficulties with conventional therapy. This trial was a 6-month open-label extension study.

Research detailed the reported adverse events in studies involving adult participants (ages 18-65).

The studies excluded participants with severe hepatic or renal impairment due to potential interactions or risks.

Important Note: The information presented here describes what was reported in specific studies. It is not an assessment of suitability or a recommendation for treatment.

Key Studies & References Assessment of Long-Term Outcomes and Quality of Life with Compound X Combination Therapy: 6-Month Open-Label Extension Study (Trial 2)

Frequently Asked Questions (FAQ)

Common questions about Ambroxol HCl (FAQ)


Q: Is Ambroxol HCl the same as a cough suppressant?

Ambroxol is classified as a mucolytic (mucus-clearing) agent, meaning it works to loosen and thin mucus. Official documents advise against combining it with cough suppressants (antitussives) because suppressing the cough reflex can prevent the body from clearing the mucus that Ambroxol is working to make more manageable.


Q: What is the main difference between Ambroxol HCl and a standard expectorant?

Ambroxol is classified as a mucolytic/secretolytic agent; its primary function is to chemically break down and thin thick mucus and encourage the body to secrete it. A standard expectorant works mainly by increasing the volume of fluid in the airways to help make secretions less viscous and easier to clear.


Q: Does Ambroxol HCl help with a dry cough or only a wet cough?

Official information defines Ambroxol's role as a treatment for respiratory conditions where the airways are congested with thick or viscous mucus, which is typically associated with a wet cough. It is not generally indicated for a dry cough where mucus clearance is not the primary issue.


Q: Is it okay to take Ambroxol HCl with pain relievers like paracetamol or ibuprofen?

Regulatory interaction documents primarily focus on antibiotics and cough suppressants. No specific unfavourable interactions are documented or required as a warning constraint between Ambroxol HCl and common non-opioid pain relievers.


Q: Can Ambroxol HCl cause drowsiness or affect driving?

Official adverse reaction lists include headache and dizziness, particularly in the Nervous System Disorders category. Although these side effects are generally uncommon, if these symptoms occur, regulatory documents state that they could potentially impair the ability to drive or operate machinery.


Q: Why do official sources sometimes recommend taking Ambroxol HCl with food?

Patient instructions in official guidelines recommend taking immediate-release formulations, such as tablets, after a meal along with fluid. This practice is generally suggested to potentially minimize mild gastrointestinal side effects, such as nausea or abdominal pain, which are listed as common adverse reactions.


Q: Is Ambroxol HCl considered an antihistamine?

No. Official regulatory documents consistently classify Ambroxol HCl as a mucolytic and secretolytic agent. It belongs to a separate group of medicines that specifically targets mucus production and clearance, and it does not act as an antihistamine.


Q: What do research studies conclude about the general effectiveness of Ambroxol HCl?

The drug’s official purpose is based on its ability to liquefy secretions and enhance mucus transport. Studies have examined its intended mucolytic action by reporting findings related to symptom scores or respiratory conditions associated with excessive mucus. Research evidence supports its role in aiding mucus clearance.


Q: How does Ambroxol HCl compare to bromhexine in terms of regulatory classification?

Ambroxol is structurally defined as the synthetic active metabolite of the older molecule, bromhexine. Both are classified in the same therapeutic category (mucolytics) and share a similar mechanism of action related to breaking down mucus.


Q: Does Ambroxol HCl have any known effects on heart rate or blood pressure?

Adverse reaction lists for Ambroxol HCl note that in rare cases (with an unknown frequency), the medicine has been associated with cardiovascular symptoms such as palpitations (a rapid or irregular heart rate) or changes in blood pressure. If a patient experiences these symptoms, it is noted in official guidance to seek medical review.


Q: Can Ambroxol HCl be taken for a sore throat?

Yes, some specific formulations, such as lozenges, are officially indicated for the relief of pain in acute sore throat. This effect is attributed to the medicine’s local anesthetic action on the mucous membranes, as described in certain regulatory documents.


Q: How quickly does Ambroxol HCl typically start to work for cough symptoms?

Regulatory documents focusing on pharmacokinetics (how the body handles the drug) state that Ambroxol HCl is rapidly absorbed after oral administration. Peak concentrations of the medicine in the blood typically occur about 1 hour after taking a dose.


Q: What happens if I forget to take a dose of Ambroxol HCl?

Official patient instructions generally advise that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, official guidelines indicate that the missed dose should be skipped to prevent taking a double dose. Patients are advised to continue with their regular schedule.


Q: Does Ambroxol HCl have any effect on asthma symptoms?

Ambroxol’s primary action is to clear thick mucus. Regulatory precautions advise exercising care when using the drug in asthmatic patients. Some specialized formulations have been subject to research for other respiratory conditions that include asthma.


Q: Is Ambroxol HCl a steroid or antibiotic?

No. Ambroxol is pharmacologically defined by regulatory bodies as a mucolytic and secretolytic agent. It is a mucoactive drug and is classified as neither a steroid (corticosteroid) nor an antibiotic.


Q: Can Ambroxol HCl be used if I am breastfeeding?

Regulatory information indicates that Ambroxol is excreted into breast milk. For this reason, official guidance states that its use is not recommended while breastfeeding. If use during the nursing period is considered, a medical professional should be consulted.


Q: Can Ambroxol HCl be used if I have kidney stones?

Regulatory precautions do not specifically mention kidney stones (renal calculi). However, they do require a dose adjustment or extended dosing intervals for patients with severe renal impairment. This is a key safety constraint related to the kidney's ability to clear the medicine's metabolites from the body.

How should Ambroxol HCl be stored and disposed of?

How to Store and Dispose of Ambroxol HCl?

Ambroxol HCl must be stored according to specific regulatory conditions to maintain its quality and efficacy.

Storage Requirements

Condition Requirement
Temperature Do not store above 30 C.
Protection Must be protected from light and stored in its original package.
Safety The medicine must be kept out of reach of children.
Stability For liquid formulations, stability rules mandate that the product is discarded after a defined period (e.g., one month) following the first opening of the bottle.

Disposal Instructions

Official regulations require that unused or expired Ambroxol HCl be disposed of in accordance with local regulations for pharmaceutical waste. Disposal must not occur via wastewater or household garbage. It is explicitly required to avoid release to the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ambroxol HCl found in:

A-Z Index: